← Back to Search

IV Diuretics for Heart Failure

N/A
Recruiting
Led By Stephen Greene
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥18 years of age
Be older than 18 years old
Must not have
New diagnosis of heart failure
End-stage kidney disease requiring chronic dialysis therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if IV diuretics can help improve heart failure symptoms when taken at home. #OUTPATIENT-WHF

Who is the study for?
This trial is for adults over 18 with worsening heart failure who need IV diuretics, as judged by their doctor. They must have completed a health survey and be able to consent. It's not for those with heart devices, severe kidney disease on dialysis, new heart failure diagnosis, pregnancy, high fever at screening or any condition affecting study compliance.
What is being tested?
The OUTPATIENT-WHF study tests if giving IV diuretics in an outpatient clinic can effectively treat worsening heart failure compared to the usual initial hospitalization strategy. Patients will either receive treatment in the clinic or be hospitalized.
What are the potential side effects?
While specific side effects are not listed here, generally IV diuretics can cause electrolyte imbalances, kidney issues or low blood pressure. The exact side effects will depend on individual patient conditions and responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been recently diagnosed with heart failure.
Select...
I am on long-term dialysis for end-stage kidney disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Health status as measured by EuroQOL-5 dimensions (EQ5D) utility index
Health status as measured by EuroQOL-5 dimensions (EQ5D) visual analog scale (VAS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Initial outpatient management strategy, including outpatient IV diuretics in clinicExperimental Treatment1 Intervention
Group II: Initial hospitalization-based management strategyExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,462 Previous Clinical Trials
2,968,850 Total Patients Enrolled
Stephen GreenePrincipal InvestigatorDuke University

Media Library

Initial Hospitalization-based Management Strategy Clinical Trial Eligibility Overview. Trial Name: NCT05704595 — N/A
Congestive Heart Failure Research Study Groups: Initial outpatient management strategy, including outpatient IV diuretics in clinic, Initial hospitalization-based management strategy
Congestive Heart Failure Clinical Trial 2023: Initial Hospitalization-based Management Strategy Highlights & Side Effects. Trial Name: NCT05704595 — N/A
Initial Hospitalization-based Management Strategy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05704595 — N/A
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top